Mr. Stephen Lockyer reports

MEDX HEALTH CORP. ANNOUNCES CONVERSION OF $2.965 MILLION OF SECURED CONVERTIBLE DEBENTURES

Effective Nov. 17, 2023, $2,965,000 of secured convertible debentures of MedX Health Corp. were fully redeemed pursuant to exercise of the conversion rights by the holders, resulting in the issuance of 59.3 million common shares and 59.3 million share purchase warrants exercisable at 20 cents until Dec. 31, 2027.

"This conversion of this Secured Debt sends a strong message of confidence in the future of MedX and continued support by the former debt-holders, and has eliminated of all the secured debt from the Company's Balance Sheet. This positive step will greatly help the Company move forward with the ongoing roll-out of its SIAscopy on DermSecure telemedicine platform," said Stephen Lockyer, CEO of MedX.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformite Europeenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com .